5 Stocks Improving Performance Of The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 14 points (0.1%) at 16,456 as of Friday, Jan. 3, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,718 issues advancing vs. 1,181 declining with 172 unchanged.

The Drugs industry currently sits up 0.2% versus the S&P 500, which is unchanged. Top gainers within the industry include Novo Nordisk A/S ( NVO), up 1.2%, Novartis ( NVS), up 0.6%, Sanofi ( SNY), up 0.5% and AstraZeneca ( AZN), up 0.5%. On the negative front, top decliners within the industry include Herbalife ( HLF), down 5.3%, Illumina ( ILMN), down 2.3% and Regeneron Pharmaceuticals ( REGN), down 0.9%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Allergan ( AGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Allergan is up $1.22 (1.1%) to $111.50 on light volume. Thus far, 618,550 shares of Allergan exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $110.69-$112.07 after having opened the day at $110.75 as compared to the previous trading day's close of $110.28.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $33.0 billion and is part of the health care sector. Shares are down 0.7% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Allergan a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, increase in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Allergan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Eli Lilly and Company ( LLY) is up $0.27 (0.5%) to $51.00 on light volume. Thus far, 915,089 shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 6.0 million shares. The stock has ranged in price between $50.67-$51.20 after having opened the day at $50.78 as compared to the previous trading day's close of $50.73.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $57.5 billion and is part of the health care sector. Shares are down 0.5% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Eli Lilly and Company a buy, 2 analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Bristol-Myers Squibb Company ( BMY) is up $0.63 (1.2%) to $52.90 on light volume. Thus far, 1.4 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 7.0 million shares. The stock has ranged in price between $52.37-$53.18 after having opened the day at $52.38 as compared to the previous trading day's close of $52.27.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $87.5 billion and is part of the health care sector. Shares are unchanged year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, solid stock price performance, impressive record of earnings per share growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Bristol-Myers Squibb Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Merck ( MRK) is up $0.40 (0.8%) to $49.89 on light volume. Thus far, 2.7 million shares of Merck exchanged hands as compared to its average daily volume of 12.6 million shares. The stock has ranged in price between $49.46-$50.00 after having opened the day at $49.49 as compared to the previous trading day's close of $49.49.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $146.2 billion and is part of the health care sector. Shares are down 1.1% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Merck a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Johnson & Johnson ( JNJ) is up $0.74 (0.8%) to $91.77 on light volume. Thus far, 2.1 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 7.1 million shares. The stock has ranged in price between $91.26-$92.17 after having opened the day at $91.30 as compared to the previous trading day's close of $91.03.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $258.4 billion and is part of the health care sector. Shares are down 0.6% year to date as of the close of trading on Thursday. Currently there are 8 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

Dow Posts First Gain in Nine Sessions; Oil Jumps

Dow Posts First Gain in Nine Sessions; Oil Jumps